

Intensity (counts)
12000
10000
8000
6000
4000
2000
0
5
10
15
20
25
30
2Theta (°)

FIG. 1



Treatment day 16-37
Vehicle (20% HP-β-CD)
Compound A3 _ 30 mg/kg/QD
Compound A3 _ 100 mg/kg/QD
Mean Tumor Volume +/- SEM (mm3)
2500
2000
1500
1000
500
0
0
10
20
30
40
Days Post Tumor Implant

FIG. 2




Treatment day 3-30
Vehicle (20% HP-β-CD)
Compound A3 _30mg/kg/QD
Compound A3 _50mg/kg/QD
Compound A3 _100mg/kg/QD
Percent survival
100
50
0
0
20
40
60
80
100
120
Days Post Tumor Inoculation

FIG. 3

A


Percent Survival
100
80
60
40
20
0
0
10
20
30
40
50
* * ***
Compound A1
venetoclax
azacitidine
Days Post Tumor Engraftment
vehicle control
azacitidine 2 mg/kg
venetoclax 100 mg/kg
Compound A1 30 mg/kg
azacitidine + venetoclax
Compound A1 + venetoclax
Compound A1 + azacitidine + venetoclax

B



Percent Survival
100
80
60
40
20
0
0
10
20
30
40
50
60
70
* * * *
* *
Compound A1
venetoclax
azacitidine
Days Post Tumor Engraftment
vehicle control
azacitidine 2 mg/kg
venetoclax 100 mg/kg
Compound A1 10 mg/kg
azacitidine + venetoclax
Compound A1 + venetoclax
Compound A1 + azacitidine + venetoclax

FIG. 4



Contour plot for maxR
p-values
≤0.001
0.01
0.05
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.1
0.05
0.01
≤0.001
Compound A3 (μM)
1
0.25
0.0625
0.0156
0.004
0.001
0.0003
Venetoclax (μM)
0.0003
0.0016
0.008
0.04
0.2
1

FIG. 5A



Contour plot for maxR
p-values
≤0.001
0.01
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.05
0.01
≤0.001
Compound A3 (μM)
1
0.25
0.0625
0.0156
0.004
0.001
Venetoclax (μM)
6E-05 0.0003 0.0016 0.008 0.04 0.2 1 5 25
Azacitidine (μM)
0.002 0.008 0.04 0.2 1

FIG. 5B



MOLM-13
(KMT2Ar/FLT3ITD)
Contour plot for maxR
p-values
≤0.001
0.01
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.05
0.01
≤0.001
Compound A4
1e+01
1e+00
1e-01
5e-02
1e-02
1e-03
0.0015
0.0150
0.1500
1.5000
3.0000
Decitabine (μM)

FIG. 6A



Contour plot for maxR
p-values
≤0.001
0.01
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.05
0.01
≤0.001
Compound A4
1e+01
1e+00
1e-01
5e-02
1e-02
1e-03
Decitabine (μM)
0.0015
0.0150
0.1500
1.5000
3.0000
Venetoclax (μM)
0.00002
0.0002
0.002
0.02
0.2

FIG. 6B



OCI-AML3
(NMP1c)
Contour plot for maxR
p-values
≤0.001
0.01
0.1
0.3
↑Antagonism
↓Synergy
0.2
0.05
0.01
≤0.001
Compound A4
1e+01
1e+00
1e-01
5e-02
1e-02
1e-03
Decitabine (μM)
0.0015
0.0150
0.1500
1.5000
3.0000

FIG. 7A



Contour plot for maxR
p-values
≤0.001
0.01
0.3
0.05
0.01
≤0.001
Compound A4
1e+01
1e+00
1e-01
5e-02
1e-02
1e-03
Decitabine (μM)
0.0015
0.0150
0.1500
1.5000
3.0000
Venetoclax (μM)
0.00002
0.0002
0.002
0.02
0.2

FIG. 7B